Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).


Related Content

NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost
NICE Pans Roche’s Perjeta For Breast Cancer On Clinical, Cost Grounds
Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
Final Perjeta Overall Survival Data Delayed By Its Efficacy
Lundbeck Pins Hopes On New Product Launches, Ex-Europe Growth To Reverse Revenue Drain
Disease Severity Underlies Advisory Committee Support For Kynamro
Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline
Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
Perjeta Approval Heralds Roche’s Next Wave Of Breast Cancer Drugs
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts